Arena Pharmaceuticals, Inc. (ARNA)
|52 Week Range||99.97-100|
|1y Target Est||-|
|DCF Unlevered||ARNA DCF ->|
|DCF Levered||ARNA LDCF ->|
|Debt / Equity||6.12%||Neutral|
Upgrades & Downgrades
Latest ARNA news
Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals
11 March 2022
Shares of Pfizer Inc. PFE, +2.32% were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immun...
7 Biotech Stocks With Key Catalysts in March
9 March 2022
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on Invest...
11 Marijuana Stocks on Fire to Close February
28 February 2022
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make...
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
24 February 2022
Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.
Top 3 weed stocks to put on your watch list this year
17 February 2022
The marijuana industry has seen sharp growth year on year.
Pharma Giants Go After $10 Billion Market With RSV Drugs
18 January 2022
GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentia...
Cannabis Watch: Pfizer's Arena Pharma deal may lead drug company to a cannabis-based treatment
23 December 2021
Pfizer Inc.'s presentation of its pending $6.7 billion acquisition of clinical-stage drug company Arena Pharmaceuticals Inc. contained no mention of cannabis.
Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?
22 December 2021
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Abivax: Potentially The Next Arena Pharmaceuticals, Most Ideal Big Pharma M&A Target In 2022
15 December 2021
Arena Pharmaceuticals got acquired by Pfizer for US$ 6.7 Bn (~100% valuation) on December 12th. As a result, the market for late-stage oral IBD candidates that big pharma can acquire is thinning.